Short Interest in Fortress Biotech, Inc. (NASDAQ:FBIOP) Declines By 41.7%

Fortress Biotech, Inc. (NASDAQ:FBIOP) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 700 shares, a drop of 41.7% from the June 30th total of 1,200 shares. Based on an average trading volume of 17,700 shares, the days-to-cover ratio is currently 0.0 days.

Fortress Biotech Price Performance

Shares of NASDAQ FBIOP traded down $0.41 during mid-day trading on Friday, reaching $9.17. 47,566 shares of the company traded hands, compared to its average volume of 15,352. Fortress Biotech has a fifty-two week low of $6.40 and a fifty-two week high of $18.00. The stock has a fifty day simple moving average of $13.83 and a 200-day simple moving average of $14.69.

Fortress Biotech Dividend Announcement

The firm also recently declared a monthly dividend, which was paid on Sunday, June 30th. Shareholders of record on Saturday, June 15th were given a $0.1953 dividend. The ex-dividend date was Friday, June 14th. This represents a $2.34 annualized dividend and a yield of 25.56%.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.